The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Avanos Medical sees growth from SNS and PMR, with strong demand in enteral feeding and RFA. AVNS boosts portfolio via Nexus deal, divestitures and exit of underperforming segments. Avanos Medical ...

Avanos Medical (AVNS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

It has been about a month since the last earnings report for Avanos Medical (AVNS). Shares have lost about 0.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Avanos Medical, Inc. AVNS is well poised for growth in the coming quarters, backed by its impressive product line. A solid first-quarter 2022 performance, along with continued focus on its Research ...

Diamond Hill Capital, an investment management company, released its “Small Cap Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q1, markets were uneven due to ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Avanos Medical posted robust Q2 growth in SNS and solid RFA sales in Pain Management and Recovery. AVNS' transformation plan includes divestitures and acquisitions. Tariffs and FX volatility remain ...

Avanos Medical, Inc. AVNS is well-poised for growth in the coming quarters, courtesy of its impressive product line. The optimism led by a solid first-quarter 2024 performance and continued focus on ...

Avanos Medical, Inc. AVNS is well-poised for growth in the coming quarters, courtesy of its impressive product line. The optimism, led by a solid fiscal third-quarter 2024 performance and continued ...